Jazz Pharmaceuticals
JAZZ
231.19
-0.20
-0.09%
Jazz Pharmaceuticals
US · JAZZ
#1123 by market cap
Listed 1970
231.19
-0.20
-0.09%
Live - 5344 symbols - heartbeat 30s ago
· 2026-10-08 04:15
Pre-market
229.85
-0.58%
After-hours
231.19
0.00%
Overnight
231.85
+0.29%
- Market cap
- 15.01B
- P/E (TTM)i
- 15.82
- P/Bi
- 3.13
- EPSi
- -5.84
- Div yieldi
- 0.00%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on JAZZ?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 17 analysts
Buy
Avg price target
303.06 +31.1%
Price target rangecurrent 231.19
Low271.00
Avg303.06
High337.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-09-30 | Citi | -- | BUY | 325.00 |
| 2026-09-28 | Piper Sandler | -- | BUY | 310.00 |
| 2026-09-24 | Goldman Sachs | -- | BUY | 337.00 |
| 2026-09-14 | UBS | -- | BUY | 337.00 |
| 2026-09-11 | UBS | -- | BUY | 337.00 |
| 2026-09-10 | Barclays | -- | BUY | 271.00 |
| 2026-09-09 | Piper Sandler | -- | BUY | 310.00 |
| 2026-09-01 | Truist Financial | -- | BUY | -- |
| 2026-08-31 | TD Cowen | -- | BUY | 300.00 |
| 2026-08-31 | CCORF | -- | BUY | 300.00 |
| 2026-08-31 | Needham | -- | BUY | 310.00 |
| 2026-08-28 | RBC Capital | -- | BUY | 299.00 |
| 2026-08-26 | TD Cowen | -- | BUY | 300.00 |
| 2026-08-26 | CCORF | -- | BUY | 300.00 |
| 2026-08-26 | Piper Sandler | -- | BUY | 310.00 |
| 2026-08-26 | Truist Financial | -- | BUY | 281.00 |
| 2026-08-26 | Morgan Stanley | -- | BUY | 322.00 |
| 2026-08-26 | Deutsche Bank | -- | BUY | 300.00 |
| 2026-08-26 | Needham | -- | BUY | 310.00 |
| 2026-08-25 | TD Cowen | -- | BUY | 300.00 |
| 2026-08-25 | BofA Securities | -- | BUY | 307.00 |
| 2026-08-25 | RBC Capital | -- | BUY | 277.00 |
| 2026-08-13 | Morgan Stanley | -- | BUY | 283.00 |
| 2026-08-11 | CCORF | -- | BUY | 300.00 |
| 2026-08-11 | UBS | -- | BUY | 315.00 |
Quant vs Street three independent views, side by side
StockVane factor grade
A-
Momentum strategy signal
Buy
Analyst consensus
Buy
All 3 views agree: bullish.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: UBS moved from Hold to Buy on 2026-05-19.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-05-19 | UBS | HOLD → BUY | 307.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-03 | After close | ±6.48% | +3.99% (in line) |
| 2026/Q1 | 2026-05-05 | After close | ±6.19% | +7.68% (beat) |
| 2025/Q4 | 2026-02-24 | After close | ±7.84% | +13.23% (beat) |
| 2025/Q3 | 2025-11-05 | After close | ±7.81% | -2.31% (in line) |
| 2025/Q2 | 2025-08-05 | After close | ±10.58% | -6.42% (in line) |
| 2025/Q1 | 2025-05-06 | After close | ±11.47% | -8.75% (in line) |
| 2024/Q4 | 2025-02-25 | After close | ±8.47% | +3.22% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±7.79% | +6.75% (in line) |
| 2024/Q2 | 2024-07-31 | After close | ±9.90% | +3.75% (in line) |
| 2024/Q1 | 2024-05-01 | After close | ±8.33% | -0.92% (in line) |
| 2023/Q4 | 2024-02-28 | After close | ±8.73% | -8.33% (in line) |
| 2023/Q3 | 2023-11-08 | After close | ±7.84% | -9.14% (beat) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 04:15:57 · For reference only, not investment advice and not tailored to your situation.